Skip to content

Medical emergency? What to do

U.S. OKs use of Genentech's Avastin in lung cancer

3-RXPublished October 13, 20062 min read

Key points

  • U.S. regulators agreed to expand the use of Genentech Inc.'s drug Avastin, now used against colon cancer, to include treatment of the most common type of lung cancer, the company said on Wednesday.
  • The FDA nod, while expected, "is a billion-dollar-plus opportunity for Genentech," said Mike King, an analyst at Rodman & Renshaw.
  • Approval was based on a study showing Avastin and chemotherapy resulted in a 25 percent improvement in survival compared to chemotherapy alone, the South San Francisco, California-based company said.
  • U.S. sales of Avastin, which is being studied as a treatment for a range of solid tumors, totaled $1.13 billion last year.

U.S. regulators agreed to expand the use of Genentech Inc.'s drug Avastin, now used against colon cancer, to include treatment of the most common type of lung cancer, the company said on Wednesday.

Avastin, the first drug designed to starve tumors of blood and nutrients, was approved as an initial treatment, in combination with chemotherapy, for patients with non-small cell lung cancer.

The FDA nod, while expected, "is a billion-dollar-plus opportunity for Genentech," said Mike King, an analyst at Rodman & Renshaw.

The company's shares, which fell 2 percent to close at $84.15 on the New York Stock Exchange, were little changed at $84.07 after hours.

Approval was based on a study showing Avastin and chemotherapy resulted in a 25 percent improvement in survival compared to chemotherapy alone, the South San Francisco, California-based company said.

"Lung cancer is responsible for more than one-third of all U.S. cancer deaths, killing more people than breast, prostate, colon, liver and kidney cancers combined," Laurie Fenton, president of the Lung Cancer Alliance, said.

U.S. sales of Avastin, which is being studied as a treatment for a range of solid tumors, totaled $1.13 billion last year.

King estimated that annual sales will reach $4 billion by 2009.

Susan Desmond-Hellmann, head of product development at Genentech, said the lung cancer approval would make another 65,000 to 81,000 patients candidates for the drug.

The company put the monthly price of Avastin at about $4,400 for patients with colon cancer, but said a higher dose is needed for advanced lung cancer, bringing the monthly cost to $8,800 and the average cost of a course of therapy to about $56,000.

Genentech said it plans to cap the overall expense of Avastin to $55,000 per year per eligible patient, regardless of whether they are insured, for any FDA-approved indication.

"It's a small concession," King said, referring to the price cap, but added that it makes sense for makers of expensive cancer drugs to ensure patient access.

The company, which is majority owned by Swiss drugmaker Roche Holding AG, plans to begin the price program in January.

In addition, Genentech said it has doubled its contribution to independent charities that provide co-pay assistance to a total of $50 million.

The FDA last month asked for more information about the safety and efficacy of Avastin as a treatment for breast cancer, delaying a decision on the company's application to expand Avastin's use into that patient population.

King said an FDA decision on Avastin's use in breast cancer is unlikely before late next year.

Side effects of the drug include low white blood cell count, fatigue, high blood pressure, infection and hemorrhage.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underLung Cancer

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.